Follistatin 315 Peptide Therapy
Benefits, Side Effects, Cost & Protocols
Follistatin 315 is a specific isoform of follistatin that is membrane-bound and acts primarily in a localized, autocrine/paracrine manner. It inhibits myostatin and activin locally in muscle tissue, making it of interest for targeted muscle growth applications.
Clinically Reviewed
Reviewed by Alex Evans, PharmD, MBA · Updated May 2026
Evidence-Based
Sourced from FDA, PubMed & ClinicalTrials.gov · View sources
How Follistatin 315 Works
Binds activin and myostatin locally within muscle tissue due to heparin-binding domain, providing targeted inhibition rather than systemic effects.
Follistatin 315 FAQ
What is FOLLISTATIN 315?
Follistatin 315 is a tissue-bound isoform of follistatin with more localized myostatin-blocking activity compared to the circulating Follistatin 344 variant.
How does FOLLISTATIN 315 work?
Binds activin and myostatin locally within muscle tissue due to heparin-binding domain, providing targeted inhibition rather than systemic effects.
Is FOLLISTATIN 315 legal to buy?
FOLLISTATIN 315 is sold as a research chemical for laboratory use only. It is not approved for human use by the FDA. Regulations vary by jurisdiction.
Where can I buy FOLLISTATIN 315?
FOLLISTATIN 315 is available as a research compound from verified online vendors. Always verify third-party testing before purchasing.
What category does FOLLISTATIN 315 belong to?
FOLLISTATIN 315 is primarily classified as a growth hormone secretion peptide. Peptides that stimulate or support growth hormone release, including GHRH analogs, GHRPs, and direct GH compounds for muscle, recovery, and anti-aging research.
What are the research benefits of FOLLISTATIN 315?
FOLLISTATIN 315 has been studied for: Localized myostatin inhibition, Targeted muscle support, Lean mass preservation. Tissue-bound follistatin isoform; more targeted than FS-344.
Key Studies
40 total on PubMed22 human trialsDynamics of inhibin subunit and follistatin mRNA during development of normal and polycystic ovary syndrome follicles
Fujiwara T, Sidis Y, Welt C et al
J Clin Endocrinol Metab
Inhibin subunit mRNA increases with follicle maturity; polycystic ovary syndrome shows reduced inhibin alpha subunit levels
Activin B Induces Noncanonical SMAD1/5/8 Signaling via BMP Type I Receptors in Hepatocytes: Evidence for a Role in Hepcidin Induction by Inflammation in Male Mice
Canali S, Core AB, Zumbrennen-Bullough KB et al
EndocrinologyAnimal
Activin B stimulates hepcidin via SMAD1/5/8 signaling; follistatin-315 blunts hepcidin induction during inflammation
An engineered human follistatin variant: insights into the pharmacokinetic and pharmocodynamic relationships of a novel molecule with broad therapeutic potential
Datta-Mannan A, Yaden B, Krishnan V et al
J Pharmacol Exp TherPhase 1
Engineered follistatin-Fc fusion showed 100-fold improvement in half-life and robust dose-dependent effects in muscle atrophy models
Increased activin bioavailability enhances hepatic insulin sensitivity while inducing hepatic steatosis in male mice
Follistatin 315 News
Follistatin-344: Myostatin Signaling, Tissue Plasticity, and Molecular Modulation Research - HIT Consultant
HIT Consultant · 10 days ago
Follistatin-344: A Versatile Peptide Under Investigation - 3-mob.com
3-mob.com · 4 months ago
Follistatin N terminus differentially regulates muscle size and fat in vivo | Experimental & Molecular Medicine - Nature
Nature · 105 months ago
Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease - Wiley Online Library
Wiley Online Library · 210 months ago
News aggregated via Google News. Inclusion does not imply endorsement.
Ready to explore Follistatin 315 with a provider?
Take our 2-minute quiz to get matched with a board-certified provider specializing in Follistatin 315.
Take the Quiz →